Agios's 15min chart shows KDJ Death Cross, bearish Marubozu pattern.

The 15-minute chart for Agios has triggered a KDJ Death Cross and a Bearish Marubozu at 13:45 on August 15, 2025. This suggests that the momentum of the stock price is shifting towards the downside, with a potential for further decreases. Sellers currently control the market, and it is likely that the bearish momentum will continue.

Agios Pharmaceuticals (AGIO) has seen a significant shift in its 15-minute chart, with a KDJ Death Cross and a Bearish Marubozu appearing at 13:45 on August 15, 2025. These technical indicators suggest that the stock's momentum is turning downwards, with potential for further declines. The market is currently dominated by sellers, indicating that bearish momentum is likely to persist.

The KDJ (Kaufman Adaptive Moving Average) Death Cross occurs when the KDJ line crosses below the signal line, signaling a potential reversal in the stock's price trend. The Bearish Marubozu, a candlestick pattern, signifies strong bearish momentum and a lack of resistance from buyers. These indicators suggest that Agios Pharmaceuticals may continue to face downward pressure.

Investors should closely monitor Agios Pharmaceuticals for any further developments. The stock has been under scrutiny due to recent FDA safety concerns involving its anemia treatment Pyrukynd. The FDA’s Adverse Event Reporting System (FAERS) revealed four deaths in patients who had taken the drug, prompting a 23% dip in the stock's lowest point on Monday, July 11, 2025 [2]. Despite Agios' clarification that the deaths have not altered the drug's benefit-risk profile, the stock has remained volatile, with a 3% increase from its closing price on Friday, July 8, 2025, to $36.16 by the closing bell [2].

The technical analysis suggests that Agios Pharmaceuticals may continue to face downward pressure. The stock has been downgraded to a "Sell Candidate" due to weak technical signals, with few positive indicators and a general sell signal from the relation between short and long-term moving averages [1]. Additionally, the stock has found support at $35.00, but the risk is considered medium due to its average daily volatility of 11.50% [1].

Investors should remain cautious and monitor the stock closely for any further developments. Agios Pharmaceuticals' regulatory filing for Pyrukynd in the U.S. is due by September 7, which may influence the stock's performance. The upcoming trading day on Monday, August 11, is expected to open at $36.31, with a possible trading interval of $34.67 to $36.85, indicating a potential 6.29% move during the day [1].

References:
[1] https://stockinvest.us/stock/AGIO
[2] https://www.biospace.com/drug-development/report-of-patient-deaths-sends-agios-shares-seesawing